2. Dao T, Green AE, Kim YA, Bae SJ, Ha KT, Gariani K, et al. Sarcopenia and muscle aging: a brief overview. Endocrinol Metab (Seoul) 2020;35:716-32.
[CROSSREF] [PUBMED] [PMC]
3. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16-31.
[CROSSREF] [PUBMED]
4. Kim YK, Yi SR, Lee YH, Kwon J, Jang SI, Park SH. Effect of sarcopenia on postoperative mortality in osteoporotic hip fracture patients. J Bone Metab 2018;25:227-33.
[CROSSREF] [PUBMED] [PMC]
5. Anker SD, Morley JE, von Haehling S. Welcome to the ICD-10 code for sarcopenia. J Cachexia Sarcopenia Muscle 2016;7:512-4.
[CROSSREF] [PUBMED] [PMC]
6. Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr 1997;127(5 Suppl):990S-991S.
[CROSSREF] [PUBMED]
7. Kim SH, Shin MJ, Shin YB, Kim KU. Sarcopenia associated with chronic obstructive pulmonary disease. J Bone Metab 2019;26:65-74.
[CROSSREF] [PUBMED] [PMC]
8. Tevosian SG, Fox SC, Ghayee HK. Molecular mechanisms of primary aldosteronism. Endocrinol Metab (Seoul) 2019;34:355-66.
[CROSSREF] [PUBMED] [PMC]
9. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016;101:1889-916.
[CROSSREF] [PUBMED]
10. Chen ZW, Hung CS, Wu VC, Lin YH. TAIPAI study group. Primary aldosteronism and cerebrovascular diseases. Endocrinol Metab (Seoul) 2018;33:429-34.
[CROSSREF]
11. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243-8.
[CROSSREF] [PUBMED]
12. Burniston JG, Saini A, Tan LB, Goldspink DF. Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo. J Mol Cell Cardiol 2005;39:395-9.
[CROSSREF] [PUBMED]
13. Kwak MK, Lee SE, Cho YY, Suh S, Kim BJ, Song KH, et al. The differential effect of excess aldosterone on skeletal muscle mass by sex. Front Endocrinol (Lausanne) 2019;10:195.
[CROSSREF] [PUBMED] [PMC]
14. Kwak MK, Lee JY, Kim BJ, Lee SH, Koh JM. Effects of primary aldosteronism and different therapeutic modalities on glucose metabolism. J Clin Med 2019;8:2194.
[CROSSREF] [PMC]
15. Aagaard NK, Andersen H, Vilstrup H, Clausen T, Jakobsen J, Dorup I. Muscle strength, Na, K-pumps, magnesium and potassium in patients with alcoholic liver cirrhosis: relation to spironolactone. J Intern Med 2002;252:56-63.
[CROSSREF] [PUBMED]
16. Lastra G, Whaley-Connell A, Manrique C, Habibi J, Gutweiler AA, Appesh L, et al. Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab 2008;295:E110-6.
[CROSSREF] [PUBMED] [PMC]
17. Kim DA, Park SJ, Lee JY, Kim JH, Lee S, Lee E, et al. Effect of CCL11 on in vitro myogenesis and its clinical relevance for sarcopenia in older adults. Endocrinol Metab (Seoul) 2021;36:455-65.
[CROSSREF] [PUBMED] [PMC]
18. Park SJ, Lee JY, Lee SH, Koh JM, Kim BJ. SLIT2 inhibits osteoclastogenesis and bone resorption by suppression of Cdc42 activity. Biochem Biophys Res Commun 2019;514:868-74.
[CROSSREF] [PUBMED]
19. Lee JY, Park SJ, Kim DA, Lee SH, Koh JM, Kim BJ. Muscle-derived lumican stimulates bone formation via integrin α2β1 and the downstream ERK signal. Front Cell Dev Biol 2020;8:565826.
[CROSSREF] [PUBMED] [PMC]
20. Kim BJ, Lee YS, Lee SY, Baek WY, Choi YJ, Moon SA, et al. Osteoclast-secreted SLIT3 coordinates bone resorption and formation. J Clin Invest 2018;128:1429-41.
[CROSSREF] [PUBMED] [PMC]
21. Gorini S, Kim SK, Infante M, Mammi C, La Vignera S, Fabbri A, et al. Role of aldosterone and mineralocorticoid receptor in cardiovascular aging. Front Endocrinol (Lausanne) 2019;10:584.
[CROSSREF] [PUBMED] [PMC]
22. Inthachart K, Manotham K, Eiam-Ong S, Eiam-Ong S. Aldosterone rapidly enhances levels of the striatin and caveolin-1 proteins in rat kidney: the role of the mineralocorticoid receptor. Endocrinol Metab (Seoul) 2019;34:291-301.
[CROSSREF]
23. Szentesi P, Csernoch L, Dux L, Keller-Pinter A. Changes in redox signaling in the skeletal muscle with aging. Oxid Med Cell Longev 2019;2019:4617801.
[CROSSREF] [PUBMED] [PMC]
24. Powers SK, Morton AB, Ahn B, Smuder AJ. Redox control of skeletal muscle atrophy. Free Radic Biol Med 2016;98:208-17.
[CROSSREF] [PUBMED] [PMC]
25. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002;82:47-95.
[CROSSREF] [PUBMED]
26. Abrigo J, Elorza AA, Riedel CA, Vilos C, Simon F, Cabrera D, et al. Role of oxidative stress as key regulator of muscle wasting during cachexia. Oxid Med Cell Longev 2018;2018:2063179.
[PUBMED] [PMC]
27. Mecocci P, Fano G, Fulle S, MacGarvey U, Shinobu L, Polidori MC, et al. Age-dependent increases in oxidative damage to DNA, lipids, and proteins in human skeletal muscle. Free Radic Biol Med 1999;26:303-8.
[CROSSREF] [PUBMED]
28. Cooper SA, Whaley-Connell A, Habibi J, Wei Y, Lastra G, Manrique C, et al. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007;293:H2009-23.
[CROSSREF] [PUBMED]
29. Fanelli C, Zatz R. Linking oxidative stress, the renin-angiotensin system, and hypertension. Hypertension 2011;57:373-4.
[CROSSREF] [PUBMED]
30. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008;51:161-7.
[CROSSREF] [PUBMED]
31. Hawkins UA, Gomez-Sanchez EP, Gomez-Sanchez CM, Gomez-Sanchez CE. The ubiquitous mineralocorticoid receptor: clinical implications. Curr Hypertens Rep 2012;14:573-80.
[CROSSREF] [PUBMED] [PMC]
32. Gomez-Sanchez EP. Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease. Curr Opin Nephrol Hypertens 2004;13:191-6.
[CROSSREF] [PUBMED]
33. Chadwick JA, Hauck JS, Lowe J, Shaw JJ, Guttridge DC, Gomez-Sanchez CE, et al. Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target. FASEB J 2015;29:4544-54.
[CROSSREF] [PUBMED] [PMC]
34. Delyani JA, Rocha R, Cook CS, Tobert DS, Levin S, Roniker B, et al. Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev 2001;19:185-200.
[CROSSREF] [PUBMED]
35. Kim BJ, Lee SH, Koh JM. Bone health in adrenal disorders. Endocrinol Metab (Seoul) 2018;33:1-8.
[CROSSREF] [PUBMED] [PMC]
36. Kim BJ, Kwak MK, Ahn SH, Kim H, Lee SH, Koh JM. Lower trabecular bone score in patients with primary aldosteronism: human skeletal deterioration by aldosterone excess. J Clin Endocrinol Metab 2018;103:615-21.
[CROSSREF] [PUBMED]